Literature DB >> 17968611

Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).

C Cooper1, F Jakob, C Chinn, E Martin-Mola, P Fardellone, S Adami, N C Thalassinos, J Melo-Gomes, D Torgerson, A Gibson, F Marin.   

Abstract

UNLABELLED: In this observational study of women with an inadequate clinical outcome to osteoporosis therapy, those with a fracture at baseline were more likely to sustain an incident fracture and have a worse health-related quality of life than those without prior fracture.
INTRODUCTION: The Observational Study of Severe Osteoporosis (OSSO) was designed to assess the fracture incidence and health-related quality of life (HRQoL) in women with an inadequate clinical outcome to osteoporosis therapy.
METHODS: Post-menopausal women (N=1,885) with established osteoporosis and an inadequate clinical response to osteoporosis drug therapy defined as: a) a fragility fracture despite therapy for one year (index fracture, N=988), or b) discontinued drug therapy due to adverse effects and/or non-compliance (N=897), were assessed during one year for HRQoL using the EQ-5D and the QUALEFFO questionnaires.
RESULTS: One hundred and sixty-six (8.8%) women had a total of 209 incident fractures (1,139 fractures/10,000 women-years). Women with an index fracture were more likely to sustain an incident fracture than those without prior fractures (hazard ratio 1.91; 95% CI: 1.37-2.66; p<0.001). Co-morbidities or antidepressant use at baseline also increased the risk of incident fracture. Median total EQ-5D Health State Values and QUALEFFO scores were worse in women with an incident fracture regardless of index fracture status. The worst scores were reported in the EQ-5D sub-domains of self-care, usual activities and pain/discomfort.
CONCLUSIONS: Women with an inadequate response to osteoporosis therapy had a high rate of incident fracture which had an adverse impact on HRQoL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968611     DOI: 10.1007/s00198-007-0488-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  44 in total

1.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

2.  A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture.

Authors:  S E Hall; R A Criddle; T L Comito; R L Prince
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

3.  Compliance with osteoporosis medications.

Authors:  Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart
Journal:  Arch Intern Med       Date:  2005-11-14

4.  Costs and quality of life associated with osteoporosis-related fractures in Sweden.

Authors:  Fredrik Borgström; Niklas Zethraeus; Olof Johnell; Lars Lidgren; Sari Ponzer; Olle Svensson; Peter Abdon; Ewald Ornstein; Karl Lunsjö; Karl Göran Thorngren; Ingemar Sernbo; Clas Rehnberg; Bengt Jönsson
Journal:  Osteoporos Int       Date:  2005-11-09       Impact factor: 4.507

5.  Validity of self-reports of fractures in perimenopausal women.

Authors:  K Honkanen; R Honkanen; L Heikkinen; H Kröger; S Saarikoski
Journal:  Am J Epidemiol       Date:  1999-09-01       Impact factor: 4.897

6.  Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.

Authors:  Michael Maricic; Jonathan D Adachi; Somnath Sarkar; Wentao Wu; Mayme Wong; Kristine D Harper
Journal:  Arch Intern Med       Date:  2002-05-27

7.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study.

Authors:  N M van Schoor; J H Smit; J W R Twisk; P Lips
Journal:  Osteoporos Int       Date:  2004-10-12       Impact factor: 4.507

9.  Early discontinuation of treatment for osteoporosis.

Authors:  Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

10.  Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.

Authors:  Carmen Turbí; Gabriel Herrero-Beaumont; Juan Carlos Acebes; Antonio Torrijos; Jenaro Graña; Roberto Miguélez; JoséAntonio Sacristán; Fernando Marín
Journal:  Clin Ther       Date:  2004-02       Impact factor: 3.393

View more
  18 in total

1.  Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.

Authors:  T Imai; S Tanaka; K Kawakami; T Miyazaki; H Hagino; M Shiraki
Journal:  Osteoporos Int       Date:  2017-03-06       Impact factor: 4.507

2.  Predicting EQ-5D-US and SF-6D societal health state values from the Osteoporosis Assessment Questionnaire.

Authors:  C M McDonough; M R Grove; A D Elledge; A N A Tosteson
Journal:  Osteoporos Int       Date:  2011-04-12       Impact factor: 4.507

3.  Bone health and deterioration in quality of life among participants from the Hertfordshire cohort study.

Authors:  E M Dennison; K A Jameson; H E Syddall; H J Martin; J Cushnaghan; A Aihie Sayer; C Cooper
Journal:  Osteoporos Int       Date:  2009-12-19       Impact factor: 4.507

4.  Validation of the simplified Chinese version of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-31).

Authors:  Chuanwen Zhou; Qianjun Li; Shushu Huang; Lu Fan; Bingjian Wang; Jian Dai; Xiaoming Tang
Journal:  Eur Spine J       Date:  2015-06-14       Impact factor: 3.134

5.  Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.

Authors:  P Hadji; V Ziller; D Gamerdinger; W Spieler; K Articus; M Baier; R Moericke; P H Kann
Journal:  Osteoporos Int       Date:  2011-11-16       Impact factor: 4.507

6.  Relationship between use of antidepressants and risk of fractures: a meta-analysis.

Authors:  V Rabenda; D Nicolet; C Beaudart; O Bruyère; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-05-26       Impact factor: 4.507

Review 7.  An updated systematic review of Health State Utility Values for osteoporosis related conditions.

Authors:  T Peasgood; K Herrmann; J A Kanis; J E Brazier
Journal:  Osteoporos Int       Date:  2009-03-07       Impact factor: 4.507

Review 8.  Vibration Therapy to Prevent Bone Loss and Falls: Mechanisms and Efficacy.

Authors:  Belinda R Beck
Journal:  Curr Osteoporos Rep       Date:  2015-12       Impact factor: 5.096

9.  Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).

Authors:  Bente L Langdahl; Gerald Rajzbaum; Franz Jakob; Dimitrios Karras; Osten Ljunggren; Willem F Lems; Astrid Fahrleitner-Pammer; J Bernard Walsh; Clare Barker; Alexey Kutahov; Fernando Marin
Journal:  Calcif Tissue Int       Date:  2009-10-13       Impact factor: 4.333

10.  Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.

Authors:  Daniel Prieto-Alhambra; Aina Pagès-Castellà; Gemma Wallace; M Kassim Javaid; Andrew Judge; Xavier Nogués; Nigel K Arden; Cyrus Cooper; Adolfo Diez-Perez
Journal:  J Bone Miner Res       Date:  2014-01       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.